Frank Campana Selected Research

pomalidomide

1/2022	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
1/2022	Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
12/2021	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
12/2021	Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
12/2021	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
10/2021	Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.
1/2021	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
1/2021	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
1/2021	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
12/2019	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frank Campana Research Topics

Disease

15	Multiple Myeloma 01/2022 - 01/2017
3	Breast Neoplasms (Breast Cancer) 11/2015 - 01/2010
3	Exanthema (Rash) 11/2015 - 01/2015
2	Pneumonia (Pneumonitis) 12/2019 - 01/2017
2	Neoplasms (Cancer) 11/2019 - 02/2015
2	Diarrhea 02/2015 - 01/2015
1	Hodgkin Disease (Hodgkin's Disease) 01/2022
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Febrile Neutropenia 01/2022
1	Body Weight (Weight, Body) 11/2020
1	Sepsis (Septicemia) 12/2019
1	Urinary Tract Infections (Urinary Tract Infection) 12/2019
1	Respiratory Tract Infections (Respiratory Tract Infection) 12/2019
1	Endometrial Neoplasms (Endometrial Cancer) 02/2015
1	Neutropenia 01/2015
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2015
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2012
1	Disease Progression 01/2010

Drug/Important Bio-Agent (IBA)

14	isatuximabIBA 01/2022 - 01/2017
13	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 01/2017
12	pomalidomideIBA 01/2022 - 05/2018
3	Monoclonal AntibodiesIBA 12/2021 - 01/2017
3	XL147IBA 11/2015 - 01/2015
2	Lenalidomide (CC 5013)FDA Link 12/2019 - 01/2017
2	Phosphatidylinositols (Phosphatidylinositol)IBA 11/2015 - 01/2015
2	Alanine Transaminase (SGPT)IBA 11/2015 - 02/2015
2	Trastuzumab (Herceptin)FDA Link 01/2015 - 01/2010
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022
1	Brentuximab VedotinIBA 01/2022
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022
1	Dacarbazine (DIC)FDA LinkGeneric 01/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 12/2021
1	Pharmaceutical PreparationsIBA 11/2020
1	Proteins (Proteins, Gene)FDA Link 11/2020
1	Myeloma ProteinsIBA 11/2020
1	Immunoglobulin G (IgG)IBA 11/2020
1	neonatal Fc receptorIBA 11/2020
1	Proteasome InhibitorsIBA 12/2019
1	AntibodiesIBA 11/2019
1	Letrozole (Femara)FDA LinkGeneric 11/2015
1	Hormones (Hormone)IBA 11/2015
1	XL765IBA 11/2015
1	human ERBB2 proteinIBA 11/2015
1	Aromatase InhibitorsIBA 11/2015
1	TOR Serine-Threonine KinasesIBA 11/2015
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2015
1	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 02/2015
1	Circulating Tumor DNAIBA 02/2015
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2015
1	Amifostine (Ethyol)FDA LinkGeneric 01/2012
1	tributyl phosphate (TBP)IBA 01/2010

Therapy/Procedure

4	Therapeutics 01/2022 - 11/2015
1	Transplantation 01/2022
1	Organ Transplantation 11/2019
1	Drug Therapy (Chemotherapy) 02/2015
1	VAP-cyclo protocol 01/2012